A federal jury has awarded $150 million to an Oregon man who claimed AbbVie Inc. misrepresented the safety of a prescription gel used to treat low testosterone.
Monday’s verdict is the first to come out of nearly 6,000 lawsuits alleging that testosterone replacement therapies caused heart attacks, strokes and blood clots. The cases also alleged that the drugs’ manufacturers, in an effort to boost sales, made false statements in an aggressive advertising and marketing campaign about how many men actually suffered from low testosterone — rather than just the effects of old age. The multidistrict litigation, which involves other defendants such as Eli Lilly & Co., has been coordinated before U.S. District Judge Matthew Kennelly of the Northern District of Illinois, who is overseeing bellwether trials in Chicago.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
